This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Stanford Institutional Review Board | |
|---|---|
| Name | Stanford Institutional Review Board |
| Founded | 1960s |
| Location | Stanford, California |
| Parent organization | Stanford University |
| Jurisdiction | United States |
Stanford Institutional Review Board
The Stanford Institutional Review Board operates as the human subjects research ethics committee at Stanford University, responsible for review, approval, and oversight of research involving human participants. It interprets federal regulations such as the Common Rule and coordinates with agencies including the Food and Drug Administration and the Office for Human Research Protections while interacting with clinical entities like Stanford Health Care and academic units such as the Stanford School of Medicine. The board engages with investigators across departments like Psychology Department, Stanford University, School of Engineering (Stanford University), and the Graduate School of Business to ensure protection of rights and welfare in line with institutional and regulatory frameworks.
The board's origins trace to institutional responses to changes prompted by incidents and regulatory developments in the 20th century, paralleling national developments sparked by debates involving Tuskegee syphilis study and policy responses influenced by the National Research Act. During the expansion of biomedical research at institutions including Harvard University and Johns Hopkins University, Stanford formalized human subjects oversight, aligning with guidance from the National Institutes of Health and adapting practices that emerged after reports such as the Belmont Report. Over decades the board evolved alongside shifting standards exemplified by revisions to the Common Rule and guidance from the World Medical Association's Declaration of Helsinki, expanding scope to cover social, behavioral, and data science research tied to centers like the Huang Center for Translational Cell Biology and laboratories in the Stanford Neurosciences Institute.
The board functions under the aegis of Stanford University's research administration and reports to officials equivalent to those in other institutions like the University of California, Berkeley's research compliance offices. Membership typically includes clinical investigators affiliated with the Stanford School of Medicine, non-scientist community representatives similar to those serving on IRBs at Massachusetts Institute of Technology and ethicists from institutions such as Georgetown University's Kennedy Institute of Ethics. The governance structure integrates subcommittees for special review domains—drug and device studies interacting with the Food and Drug Administration, genomic research linked to collaborations with the Broad Institute, and international research partnerships akin to those between Stanford University and University of Oxford. Institutional leadership coordinates policy through offices comparable to the Office for Research Protections (UR), aligning charter, quorum requirements, and conflict of interest policies with precedents set by entities like National Science Foundation panels and institutional review frameworks at Yale University.
Jurisdiction covers human subjects research conducted under the auspices of Stanford University, including projects at affiliated hospitals like Lucile Packard Children’s Hospital and fieldwork in partnerships with organizations such as World Health Organization programs and collaborators from Kaiser Permanente. The board's remit encompasses clinical trials overseen by entities like ClinicalTrials.gov registrants, behavioral studies connected to centers like the Human-Computer Interaction Group (Stanford), and secondary data analyses involving repositories similar to those maintained by the National Institutes of Health. It also addresses cross-border research consistent with bilateral agreements like those in collaborations with University of Cambridge and regional regulatory interfaces with agencies in jurisdictions such as European Medicines Agency-governed studies.
Review pathways include exempt determinations, expedited review, and full board review mirroring processes used at institutions like Columbia University and University of Pennsylvania. Investigators submit protocols through electronic systems comparable to InfoEd or IRBNet, providing consent forms, data security plans, and conflict disclosures like those required by National Institutes of Health grants. For clinical trials the board coordinates investigational new drug (IND) and investigational device exemption (IDE) oversight in concert with Food and Drug Administration requirements and institutional clinical research units resembling the Stanford Clinical and Translational Research Unit. Continuing review, adverse event reporting, and monitoring are structured to satisfy standards from Office for Human Research Protections and align with audit practices seen at Mayo Clinic research oversight offices.
Policies address informed consent, privacy protections under frameworks akin to Health Insurance Portability and Accountability Act, data sharing consistent with repositories such as the Database of Genotypes and Phenotypes, and research with vulnerable populations as guided by documents like the Belmont Report. Compliance mechanisms include routine audits, corrective action plans, and coordination with Stanford Office of General Counsel for legal interpretation, echoing compliance architectures at Duke University and University of Michigan. The board enforces conflict of interest disclosures comparable to policies from the National Science Foundation and ensures protections for populations defined in federal regulations including pregnant women, prisoners, and minors.
Training programs require investigators and staff to complete modules similar to those offered by the Collaborative Institutional Training Initiative and host workshops in partnership with centers like the Stanford Center for Biomedical Ethics and departments such as the Department of Sociology (Stanford University). Educational efforts include case conferences, online tutorials, and investigator consultations drawing on expertise from faculty affiliated with institutes like the Stanford Center for Research in Disease Prevention and visiting scholars from institutions such as Princeton University and University of Chicago.
The board has been involved in high-profile institutional reviews and public controversies paralleling scrutiny faced by IRBs at University of California, Los Angeles and Harvard University, particularly in cases involving novel neuroscience methods from labs like those at the Wu Tsai Neurosciences Institute and data-intensive social science projects similar to controversies surrounding platforms like Facebook. Investigations have prompted institutional reforms and policy updates, often coordinated with external bodies such as the Office for Human Research Protections and legal reviews involving the California Supreme Court when questions of jurisdiction, consent, and data stewardship intersected with litigation or media attention.